Pharma & Biotechpredictive risk-outcome modelingdeployed analytical workflow within clinical development; evidence comes from a conference abstract using real phase 1/2 trial data.

Exposure-response modeling for tarlatamab dose selection in advanced SCLC

Researchers used patient drug-level data and outcomes to figure out which tarlatamab dose gives the best chance of helping small cell lung cancer patients while keeping risks acceptable.

10.0

Quality
Score

Executive Brief

Business Problem Solved

Premium content - unlock to see the business problem analysis...

Value Drivers

Value Driver 1Value Driver 2

Strategic Moat

Premium content - unlock to see strategic analysis...

Premium Access

Full Analysis Available

Executive brief, technical architecture, and market positioning for this use case.

Pharmaceuticalsbiotech — $499/yr Atlas Pro — $1,499/yr

Executive Brief•Technical•Market Signal

Technical Analysis

Model Strategy

Premium content...

Data Strategy

Premium content...

Implementation Complexity

Premium content...

Scalability Bottleneck

Premium content...

Premium Access

Full Analysis Available

Executive brief, technical architecture, and market positioning for this use case.

Pharmaceuticalsbiotech — $499/yr Atlas Pro — $1,499/yr

Executive Brief•Technical•Market Signal

Market Signal

Adoption Stage

Premium content...

Differentiation Factor

Premium content...

Key Competitors

Company ACompany B

Premium Access

Full Analysis Available

Executive brief, technical architecture, and market positioning for this use case.

Pharmaceuticalsbiotech — $499/yr Atlas Pro — $1,499/yr

Executive Brief•Technical•Market Signal

Part of Application

DoseSelect AI

3 use cases in this application

Explore More

More in Pharma & Biotech→More predictive risk-outcome modeling→

Source

https://discovery.researcher.life/article/abstract-7164-exposure-efficacy-and-exposure-safety-relationships-of-tarlatamab-to-inform-dose-selection-and-benefit-risk-assessment-in-patients-with-advanced-small-cell-lung-cancer-sclc/169ac8ffba793dd3938a00a94d602235